HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on United Therapeutics (NASDAQ:UTHR) and raised the price target from $300 to $400.
July 25, 2024 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on United Therapeutics and raised the price target from $300 to $400, indicating strong confidence in the company's future performance.
The raised price target from $300 to $400 by HC Wainwright & Co. suggests a positive outlook for United Therapeutics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100